Tampa biopharma firm focused on a cure for Alzheimer’s disease raises $14.4M
July 12, 2021 - Tampa-based Alzamend Neuro Inc. (NASDAQ: ALZN), a pre-clinical stage biopharmaceutical company dedicated to developing products for neurodegenerative diseases and psychiatric disorders, celebrated its recent IPO and milestone. Company execs and others rang the opening bell at the Nasdaq stock exchange on Monday in Times Square to celebrate the recent listing on the Nasdaq Capital Market. The company has raised roughly $14.4 million in gross proceeds that will fund its next stage of developing products for the treatment and cures for dementia and Alzheimer’s disease. Both operations and human clinical trials for the products are anticipated to occur later in 2021 and beyond, according to a news release.